A Phase II Study of Binimetinib plus Belinostat for Subjects with Metastatic Uveal Melanoma
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.
To evaluate the objective response rate (ORR) utilizing RECIST v.1.1.Progression free survival (PFS), Overall survival (OS), Evaluate safety and toxicity, The banking of tumor and blood biospecimens for the conduct of mechanistic and biomarker studies
Belinostat (); Binimetinib (); PXD101 (Belinostat)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.